US2006264373A1PendingUtilityA1

Modified vitamin K-dependent polypeptides

63
Assignee: UNIV MINNESOTA A MINNESOTA CORPriority: Oct 23, 1997Filed: Mar 16, 2006Published: Nov 23, 2006
Est. expiryOct 23, 2017(expired)· nominal 20-yr term from priority
Inventors:Gary L. Nelsestuen
A61P 7/04C07K 14/745A61K 38/16C12N 9/647A61K 45/00C07K 14/47A61K 38/4846C07K 14/00
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.

Claims

exact text as granted — not AI-modified
1 - 8 . (canceled)  
     
     
         9 . A mammalian host cell comprising a vitamin K-dependent polypeptide, said vitamin K-dependent polypeptide comprising a modified GLA domain that enhances membrane binding affinity and activity of said polypeptide relative to a corresponding native vitamin K-dependent polypeptide, said modified GLA domain comprising a glutamic acid residue at position 34.  
     
     
         10 - 12 . (canceled)  
     
     
         13 . A method of increasing clot formation in a mammal comprising administering an amount of a vitamin K-dependent polypeptide effective to increase clot formation in said mammal, wherein said vitamin K-dependent polypeptide comprises a modified GLA domain that enhances membrane binding affinity and activity of said polypeptide relative to a corresponding native vitamin K-dependent polypeptide, said modified GLA domain comprising a glutamic acid residue at position 34.  
     
     
         14 . The method of  claim 13 , wherein said polypeptide is factor VII.  
     
     
         15 . The method of  claim 13 , wherein said polypeptide is factor VIIa.

Join the waitlist — get patent alerts

Track US2006264373A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.